{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:47:10Z","timestamp":1773035230042,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":467,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1111\/bcp.12281","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T04:55:25Z","timestamp":1384232125000},"page":"965-974","source":"Crossref","is-referenced-by-count":13,"title":["The H<sub>3<\/sub>antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers"],"prefix":"10.1111","volume":"77","author":[{"given":"Ahmed A.","family":"Othman","sequence":"first","affiliation":[{"name":"AbbVie Clinical Pharmacology and Pharmacometrics; AbbVie; North Chicago IL USA"},{"name":"Department of Pharmaceutics; Faculty of Pharmacy; Cairo University; Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Haig","sequence":"additional","affiliation":[{"name":"AbbVie Neuroscience Development; AbbVie; North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Florian","sequence":"additional","affiliation":[{"name":"AbbVie Neuroscience Development; AbbVie; North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Locke","sequence":"additional","affiliation":[{"name":"AbbVie Clinical Pharmacology and Pharmacometrics; AbbVie; North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lev","family":"Gertsik","sequence":"additional","affiliation":[{"name":"California Clinical Trials; Glendale CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[{"name":"AbbVie Clinical Pharmacology and Pharmacometrics; AbbVie; North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"10.1111\/bcp.12281-BIB0001|bcp12281-cit-0001","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0002|bcp12281-cit-0002","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.186.5.386","article-title":"Pathogenesis of schizophrenia: a psychopathological perspective","volume":"186","author":"Owens","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0003|bcp12281-cit-0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2004.09.003","article-title":"Clinical constructs and therapeutic discovery","volume":"72","author":"Carpenter","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1111\/bcp.12281-BIB0004|bcp12281-cit-0004","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0005|bcp12281-cit-0005","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0006|bcp12281-cit-0006","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: an attractive target for the treatment of cognitive disorders","volume":"154","author":"Esbenshade","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1111\/bcp.12281-BIB0007|bcp12281-cit-0007","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/302832a0","article-title":"Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor","volume":"302","author":"Arrang","year":"1983","journal-title":"Nature"},{"key":"10.1111\/bcp.12281-BIB0008|bcp12281-cit-0008","first-page":"27","volume-title":"Pharmacochemistry Library","author":"Blandina","year":"1998"},{"key":"10.1111\/bcp.12281-BIB0009|bcp12281-cit-0009","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1517\/13543784.13.10.1237","article-title":"Perspectives on cognitive domains, H3 receptor ligands and neurological disease","volume":"13","author":"Hancock","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/bcp.12281-BIB0010|bcp12281-cit-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2004.05.001","article-title":"Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system","volume":"103","author":"Witkin","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1111\/bcp.12281-BIB0011|bcp12281-cit-0011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/jpet.112.194126","article-title":"Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist","volume":"343","author":"Esbenshade","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/bcp.12281-BIB0012|bcp12281-cit-0012","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1111\/bcp.12281-BIB0013|bcp12281-cit-0013","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1111\/bcp.12281-BIB0014|bcp12281-cit-0014","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2125.2012.04472.x","article-title":"Safety, tolerability and pharmacokinetics of the histamine H(3) receptor antagonist, ABT-288, in healthy young adults and elderly volunteers","volume":"75","author":"Othman","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/bcp.12281-BIB0015|bcp12281-cit-0015","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1111\/bcp.12281-BIB0016|bcp12281-cit-0016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1111\/bcp.12281-BIB0017|bcp12281-cit-0017","first-page":"10","article-title":"Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients","volume":"62","author":"Cutler","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0018|bcp12281-cit-0018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0006-3223(93)90389-U","article-title":"Acute effects of neuroleptics on unmedicated schizophrenic patients and controls","volume":"34","author":"Miller","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1111\/bcp.12281-BIB0019|bcp12281-cit-0019","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1018965622014","article-title":"Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine","volume":"11","author":"Pokorny","year":"1994","journal-title":"Pharm Res"},{"key":"10.1111\/bcp.12281-BIB0020|bcp12281-cit-0020","first-page":"261","article-title":"Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4","volume":"7","author":"Seeman","year":"1992","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/bcp.12281-BIB0021|bcp12281-cit-0021","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.97.14.7673","article-title":"Schizophrenia: more dopamine, more D2 receptors","volume":"97","author":"Seeman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bcp.12281\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T13:58:44Z","timestamp":1625407124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12281"}},"subtitle":["ABT-288 in subjects with schizophrenia"],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"URL":"https:\/\/doi.org\/10.1111\/bcp.12281","relation":{},"ISSN":["0306-5251"],"issn-type":[{"value":"0306-5251","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}